Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Loading...
Community
/
Switzerland
/
Pharmaceuticals & Biotech
/
Lonza Group
Create a narrative
Lonza Group Community
SWX:LONN Community
1
Narratives
written by author
0
Comments
on narratives written by author
32
Fair Values set
on narratives written by author
Community Investing Ideas
Lonza Group
Popular
Undervalued
Overvalued
Lonza Group
AN
AnalystConsensusTarget
Consensus Narrative from 22 Analysts
Vacaville And Visp Facilities Will Secure Future Biologics Demand
Key Takeaways Sustained demand and investment in advanced manufacturing are driving stable, higher-margin growth and improved operational efficiency. Divesting non-core segments and expanding globally enhance strategic focus, revenue resilience, and long-term capital allocation efficiency.
View narrative
CHF 665.36
FV
18.0% undervalued
intrinsic discount
11.40%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
26
users have followed this narrative
14 days ago
author updated this narrative